Skip to main content
Midas Edge

Axsome Therapeutics Inc

For the period ended Dec 31, 2024. Filed Feb 18, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 18, 2025

AXSM$133.96+1.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

Page
SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS3
PART I
ITEM 1Business4
ITEM 1ARisk Factors46
ITEM 1BUnresolved Staff Comments104
ITEM 1CCybersecurity104
ITEM 2Properties105
ITEM 3Legal Proceedings106
ITEM 4Mine Safety Disclosures108
PART II
ITEM 5Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities109
ITEM 6Reserved110
ITEM 7Management’s Discussion and Analysis of Financial Condition and Results of Operations111
ITEM 7AQuantitative and Qualitative Disclosure About Market Risk126
ITEM 8Financial Statements and Supplementary Data126
ITEM 9Changes in and Disagreements with Accountants on Accounting and Financial Disclosure126
ITEM 9AControls and Procedures127
ITEM 9BOther Information128
ITEM 9CDisclosure Regarding Foreign Jurisdictions that Prevent Inspections128
PART III
ITEM 10Directors, Executive Officers and Corporate Governance129
ITEM 11Executive Compensation129
ITEM 12Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters129
ITEM 13Certain Relationships and Related Transactions and Director Independence129
ITEM 14Principal Accountant Fees and Services129
PART IV
ITEM 15Exhibits and Financial Statement Schedules130
Signatures136
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.